Acquired Company

Graphite Bio completed a merger with LENZ OpCo on March 21, 2024, and the combined company was named LENZ Therapeutics, Inc., commencing trading on Nasdaq under the ticker LENZ on March 22, 2024.

LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California. Show more

Location: 201 Lomas Santa Fe Drive, Solana Beach, CA, 92075, United States | Website: https://www.lenz-tx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

495M

52 Wk Range

$14.43 - $50.40

Previous Close

$15.82

Open

$15.80

Volume

539,746

Day Range

$14.86 - $16.00

Enterprise Value

293.8M

Cash

202.2M

Avg Qtr Burn

-11.31M

Insider Ownership

2.53%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
VIZZ (aceclidine ophthalmic solution) (LNZ100) Details Eye disease, Presbyopia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nulabeglogene autogedtemcel (nula-cel) (GPH101) Details Sickle cell disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.